Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

our and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

*Event rates are based
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ... and Chief Executive Officer, will present at the Rodman & ... New York on Tuesday, Sept. 9, 2014 ... archived webcast of the presentation will be accessible by visiting ... Events" section. About Oncothyreon ...
(Date:9/2/2014)... , September 2, 2014 ... BioData,s research and lab management services  BioData, ... service, is pleased to announce the appointment of ... most recently served as VP Marketing and Business Development ... science research and clinical applications. Previously, Culot ...
(Date:8/31/2014)... Aug. 31, 2014 Wockhardt Limited today announces ... in Anti-Infective research when two of its drugs, WCK ... Disease Product (QIDP) status from U.S. Food & Drug ... act against pathogens which have a high degree of ... Centre for Disease Control (a top U.S. government health ...
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... Veeramani, director of the E-Business Institute. Madison, Wis. ... new world of advertising, says Jerry Shereshewsky, ambassador plenipotentiary to ... student (and cohort of former Madison Mayor Paul Soglin) during ... the future of business. He was a Russian history major, ...
... are located in the MG&E Innovation Center at University ... research group ConjuGon announced on Tuesday that ... dollars from angel investors, including the firm Wisconsin ... to the firms operating costs, as well as financing ...
... gets $95,000 to help small businesses TeraMedica scans ... make deadly disease Platypus plans office move next ... UW students use more mobile computing ... implement Fiserv's ExchangeGuard , UW-Extension gets ...
Cached Biology Technology:Advertising ambassador explains the reinvention of marketing 2Advertising ambassador explains the reinvention of marketing 3ConjuGon lands $1 million angel investment 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:9/2/2014)... 2, 2014 A study published in the ... the American Academy of Child and Adolescent Psychiatry ... a psychiatric diagnosis had an increased risk of ... , Using data from the nationwide Danish registers, ... Ernst Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied ...
(Date:9/2/2014)... spiky legs and their propensity for eating anything, including ... And now research from North Carolina State University finds ... across the eastern United States. , "The good news ... kind of threat to humans," says Dr. Mary Jane ... author of a paper about the research. , The ...
(Date:9/2/2014)... stress in stride; others are done in by it. ... mechanisms of this so-called stress gap in mice with ... lead researchers to better understand the development of psychiatric ... each animal has unique experiences as it goes through ... can alter the expression of genes, and as a ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Researchers find Asian camel crickets now common in US homes 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... perspective, the answer is not as obvious as one might ... American Naturalist suggests that sex may have evolved ... central role in biology, sex is a bit of an ... a few reptileswould seem like a better way to go. ...
... emerging field of synthetic biology uses engineering techniques to ... systems or even engineer new life forms. Though these ... and applications for human health, they also raise a ... A symposium to be held by the U.S. ...
... pilot study that re-conceptualized the hospital labour room by removing ... ,28 per cent drop in infusions of artificial oxcytocin, a ... study, called PLACE (Pregnant and Labouring in an Ambient Clinical ... Birth . In addition, more than 65 ...
Cached Biology News:Study finds role for parasites in evolution of sex 2Laboring without the labor bed: It's a good thing 2
...
... DEPC-treated Water is suitable for ... prepared by incubating with 0.1% ... to remove the DEPC.DNase/RNase-Free Distilled ... use in all molecular biology ...
IHC detection kit for BrdU in cells and tissues...
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: